Insys Therapeutics (INSY) Receives Analyst Rating

Insys Therapeutics (INSY) : The consensus on Insys Therapeutics (INSY) based on 4 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Insys Therapeutics (INSY) : The most positive equity analysts on Insys Therapeutics (INSY) expects the shares to touch $28, whereas, the least positive believes that the stock will trade at $22 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $24 with an expected fluctuation of $3.46 from the mean.


Also, Jefferies maintains their rating on the shares of Insys Therapeutics (NASDAQ:INSY). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $22 per share from $17 per share. The rating by the firm was issued on August 4, 2016.

Insys Therapeutics (NASDAQ:INSY): The stock opened in the green at $13.53 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $13.7479 and a low of $13.25 for the day. The stock did not find buyers even at the lows and closed at $13.46 recording a loss of -0.37%. 708,907 shares exchanged hands during the trading day. The stock had closed at $13.51 in the previous days trading.

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution, an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.